Literature DB >> 958511

3-Methoxytyramine as an indicator of impulse-induced dopamine release in rat brain in vivo.

W Kehr.   

Abstract

3-Methoxtyramine and dopamine accumulated in vivo in rat brain after monoamine oxidase inhibition with pargyline HCl. A dose of 100 mg/kg i.p. appeared to inhibit monoamine oxidase completely and led to a linear accumulation of 3-methoxytyramine for the first 90 min. Axotomy of the ascending dopaminergic fiber tract by means of a complete transverse cerebral hemisection almost completely blocked 3-methoxytyramine formation provided that catecholamine synthesis was inhibited with H 44/68 (Methylester of alpha-methyl-p-tyrosine). The dopamine receptor agonist apomorphine, 0.5 mg/kg i.p., decreased, while the dopamine receptor antagonist haloperidol, 2 mg/kg i.p., accelerated 3-methoxytyramine formation. gamma-Butyrolactone, 750 mg/kg i.p., not only decreased 3-methoxytyramine formation per se but also effectively antagonized the haloperidol-induced increase in 3-methoxytyramine accumulation. 3-Methoxytyramine formation after inhibition of monoamine oxidase appears to be a reliable indicator of impulse-induced dopamine release and metabolism.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 958511     DOI: 10.1007/BF00507343

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  30 in total

1.  Comparing individual means in the analysis of variance.

Authors:  J W TUKEY
Journal:  Biometrics       Date:  1949-06       Impact factor: 2.571

2.  Early and selective increase in brain dopamine levels after axotomy.

Authors:  N E Andén; P Bédard; K Fuxe; U Ungerstedt
Journal:  Experientia       Date:  1972-03-15

3.  Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase.

Authors:  A Carlsson; J N Davis; W Kehr; M Lindqvist; C V Atack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

4.  The importance of the nervous impulse flow for the depletion of the monoamines from central neurones by some drugs.

Authors:  N E Andén; F Fuxe; T Hökfelt
Journal:  J Pharm Pharmacol       Date:  1966-09       Impact factor: 3.765

5.  Postmortal accumulation of 3-methoxytyramine in brain.

Authors:  A Carlsson; M Lindqvist; W Kehr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

6.  The determination of dopamine by a modification of the dihydroxyindole fluorimetric assay.

Authors:  C V Atack
Journal:  Br J Pharmacol       Date:  1973-08       Impact factor: 8.739

7.  The rate of norepinephrine synthesis measured in vivo during short intervals; influence of adrenergic nerve impulse activity.

Authors:  G C Sedvall; V K Weise; I J Kopin
Journal:  J Pharmacol Exp Ther       Date:  1968-02       Impact factor: 4.030

8.  Release by tubocurarine of dopamine and homovanillic acid from the superfused caudate nucleus.

Authors:  P J Portig; D F Sharman; M Vogt
Journal:  J Physiol       Date:  1968-02       Impact factor: 5.182

9.  Application of steady state kinetics to the estimation of synthesis rate and turnover time of tissue catecholamines.

Authors:  B B Brodie; E Costa; A Dlabac; N H Neff; H H Smookler
Journal:  J Pharmacol Exp Ther       Date:  1966-12       Impact factor: 4.030

10.  Release to the cerebral ventricles of substances with possible transmitter function in the caudate nucleus.

Authors:  P J Portig; M Vogt
Journal:  J Physiol       Date:  1969-10       Impact factor: 5.182

View more
  35 in total

1.  Involvement of brain trace amines in the behavioural effects of phenelzine.

Authors:  K M Dewar; L E Dyck; D A Durden; A A Boulton
Journal:  Neurochem Res       Date:  1988-02       Impact factor: 3.996

2.  In vivo release of endogenous dopamine, 5-hydroxytryptamine and some of their metabolites from rat caudate nucleus by phenylethylamine.

Authors:  B A Bailey; S R Philips; A A Boulton
Journal:  Neurochem Res       Date:  1987-02       Impact factor: 3.996

3.  Hyperthyroidism: specifically increased response to central NA-(alpha-)receptor stimulation and generally increased monoamine turnover in brain.

Authors:  U Strömbom; T H Svensson; D M Jackson; G Engström
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

4.  Analysis of cat retina for dopamine, dihydroxyphenylacetic acid, 3-methoxytyramine and homovanillic acid.

Authors:  D M Vaughn; D M Lindley; N R Cox; S T Simpson; W L Whitmer
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

5.  Withdrawal from repeated morphine sensitizes mice to the striatal dopamine release enhancing effect of acute morphine.

Authors:  J Airio; M Attila; T Leikola-Pelho; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

6.  Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.

Authors:  S Hjorth; K Svensson; A Carlsson; H Wikström; B Andersson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

Review 7.  Interaction of haloperidol and gamma-butyrolactone with (+)-amphetamine-induced changes in monoamine synthesis and metabolism in rat brain.

Authors:  W Kehr; W Speckenbach; R Zimmermann
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

8.  3-Methoxytyramine and normetanephrine as indicators of dopamine and noradrenaline release in mouse brain in vivo.

Authors:  W Kehr
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

9.  Pathways of dopamine metabolism in the rabbit caudate nucleus in vitro.

Authors:  A Zumstein; W Karduck; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-06       Impact factor: 3.000

10.  Catecholamine synthesis in rat brain after axotomy: interaction between apomorphine and haloperidol.

Authors:  W Kehr; A Carlsson; M Lindqvist
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.